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Background: Neurodegenerative diseases such as Alzheimer’s are associated with the aggregation of endogenous
peptides and proteins that contribute to neuronal dysfunction and loss. The glymphatic system, a brain-wide
perivascular pathway along which cerebrospinal fluid (CSF) and interstitial fluid (ISF) rapidly exchange, has recently
been identified as a key contributor to the clearance of interstitial solutes from the brain, including amyloid β.
These findings suggest that measuring changes in glymphatic pathway function may be an important prognostic
for evaluating neurodegenerative disease susceptibility or progression. However, no clinically acceptable approach
to evaluate glymphatic pathway function in humans has yet been developed.
Methods: Time-sequenced ex vivo fluorescence imaging of coronal rat and mouse brain slices was performed at
30–180 min following intrathecal infusion of CSF tracer (Texas Red- dextran-3, MW 3 kD; FITC- dextran-500, MW 500 kD)
into the cisterna magna or lumbar spine. Tracer influx into different brain regions (cortex, white matter, subcortical
structures, and hippocampus) in rat was quantified to map the movement of CSF tracer following infusion along both
routes, and to determine whether glymphatic pathway function could be evaluated after lumbar intrathecal infusion.
Results: Following lumbar intrathecal infusions, small molecular weight TR-d3 entered the brain along perivascular
pathways and exchanged broadly with the brain ISF, consistent with the initial characterization of the glymphatic
pathway in mice. Large molecular weight FITC-d500 remained confined to the perivascular spaces. Lumbar intrathecal
infusions exhibited a reduced and delayed peak parenchymal fluorescence intensity compared to intracisternal infusions.
Conclusion: Lumbar intrathecal contrast delivery is a clinically useful approach that could be used in conjunction with
dynamic contrast enhanced MRI nuclear imaging to assess glymphatic pathway function in humans.
Keywords: Intrathecal infusion, Cerebrospinal fluid (CSF), Perivascular space, Neurodegenerative disease, Alzheimer’s
disease, Traumatic brain injuryBackground
Neurodegenerative disorders such as Alzheimer’s disease
(AD) are characterized by progressive loss of neurons,
sensory and motor impairments, and severe cognitive
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reproduction in any medium, provided the orpeptides and accumulation of hyperphosphorylated tau in
neurofibrillary tangles are believed to contribute to the
pathophysiology of AD [2-4], while analogous misfolded
proteins aggregate in other neurodegenerative diseases,
including Huntington’s disease and amyotrophic lateral
sclerosis (ALS) [5-7]. In the case of AD, it is widely be-
lieved that amyloid deposition results from an age-related
failure of soluble Aβ clearance from the brain [8]. Although
neuroimaging approaches are now widely available to
detect the deposition of amyloid plaques and the static
evolution of plaque burden [9], no approach yet exists that
allows Aβ clearance efficiency to be directly measured ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of Aβ clearance would be a significant advance in evalu-
ating susceptibility to and progression of AD in addition
to potentially opening up a totally novel therapeutic ap-
proach to treatment.
The cerebrospinal fluid (CSF) circulation is widely
regarded as a major sink for the clearance of interstitial
fluid (ISF) and its solutes from the brain. As CSF is
reabsorbed across arachnoid granulations, along cranial
and spinal nerve sheaths, or along the brain microvascula-
ture, solutes are cleared from the cranial cavity [10–14]. In
a recent study we reported that a large proportion of sub-
arachnoid cerebrospinal fluid (CSF) recirculates through
the brain parenchyma along perivascular spaces, exchan-
ging with brain interstitial fluid (ISF) before being cleared
via peri-venous pathways [15,16]. The continuous circula-
tion of CSF along this pathway facilitates the clearance
of extracellular solutes, including soluble Aβ, from the
brain. We termed this brain-wide pathway the ‘glymphatic
system’, based upon the critical role that astroglial water
transport through the astrocytic aquaporin-4 water chan-
nel plays in facilitating CSF-ISF exchange and solute
clearance [16]. One implication of these findings is that
changes in glymphatic pathway function may contribute
to the failure of Aβ clearance in the pre-clinical stages
of AD, while a method to measure glymphatic pathway
function in clinical populations might allow AD disease
susceptibility and progression to be evaluated.
Our initial characterization of the glymphatic system
utilized in vivo two-photon microscopy and ex vivo fluor-
escence imaging of intracisternally infused CSF tracers to
map the brain-wide pathway and to quantify the efficiency
of solute clearance in mice. These approaches are not
appropriate for clinical application, given the optical
limitations of fluorescence-based imaging and the com-
plications that are associated with intracisternal infusions
in humans [17]. In the clinical setting, dynamic nuclear
imaging modalities such as magnetic resonance imaging
(MRI) are routinely used to monitor CSF flux in the
diagnosis of spontaneous intracranial hypotension (SIH)
and post-traumatic CSF rhinnorrhea or otorrhea [18,19].
These approaches permit time-sequenced three-dimensional
(3D) representation of the brain with high spatial and tem-
poral resolution of tracer distribution. In a follow-up
pre-clinical study we have successfully utilized dynamic
contrast-enhanced MRI after intrathecal infusion of
gadolinium-based contrast agent into the cisterna magna
to measure glymphatic pathway function in rats [20,21].
In contrast to intracisternal infusions, lumbar intra-
thecal injections of radio-tracer are presently used along
with computer-tomography/mylography and digital sub-
traction myelography to diagnose dural leaks associated
with SIH, pseudomeningocele, and superficial siderosis
[22,23], as well as the integrity of the spinal cord in thesetting of injury or tumor [24,25]. Lumbar intrathecal
injections are additionally used in everyday practice for
the delivery of local anesthetics [26], opioids and other
analgesics, and would thus provide an ideal delivery
route for contrast agents that could then be used in
conjunction with dynamic contrast-enhanced MRI to
evaluate glymphatic clearance in humans.
In the present pre-clinical study, we extend these recent
findings to evaluate whether perivascular CSF-ISF ex-
change within the brain can be evaluated after lumbar
intrathecal CSF tracer infusion. We compare the influx
kinetics and parenchymal distribution of these tracers with
those corresponding to intracisternal CSF tracer infusion
described previously [16,20]. Our data demonstrate that
CSF tracer infused at the lumbar spine enters the brain
through perivascular spaces and exchanges with the ISF in
a manner consistent with our previous characterization of
the glymphatic pathway, suggesting that the lumbar intra-
thecal infusion is a clinically viable contrast delivery route
to asses glymphatic function in humans.
Methods
Surgical preparation
Female Sprague–Dawley rats (200–230 g; Charles River
Labs, USA) and mixed sex C57BL/6 mice were used in
all experiments. The animals were housed under standard
laboratory conditions, with access to food and water, ad
libitum. All experiments were approved by the University
Committee on Animal Resources of the University of
Rochester and carried out according to guidelines from
the National Institutes of Health. Animals were initially
induced with isofluorane (3%), and then anesthetized
with sodium pentobarbital (50 mg/kg i.p.). Supplemen-
tal sodium pentobarbital (25 mg/kg) was given as neces-
sary. For intracisternal infusions, anesthetized rats were
fixed in a stereotaxic frame, the atlanto-occipital mem-
brane was surgically exposed followed by a durotomy,
and a 30GA needle was inserted into the cisterna magna.
For lumbar infusions, the lumbar spinal column was ex-
posed, an L2-3 laminectomy was performed, and 30GA
needle was inserted into the subarachnoid space.
Tracer infusion
In the present study, 2 different fluorescent tracers were
used: large molecular weight fixable fluorescein isothio-
cyanate (FITC)-conjugated dextran (500 kD, FITC-d500;
Invitrogen) and small molecular weight fixable Texas
Red-conjugated dextran (3 k, TR-d3; Invitrogen). FITC-
d500 and TR-d3 were selected to roughly correspond
with the molecular weights of Gd-DTPA (MW~ 1 kD)
and GadoSpin™ (MW 200 kD), which are commonly
used MRI contrast agents [27]. Tracers were constituted
in isobaric artificial CSF at a concentration of 0.25%. In
a companion study [20], we evaluated CSF-ISF exchange
Yang et al. Journal of Translational Medicine 2013, 11:107 Page 3 of 9
http://www.translational-medicine.com/content/11/1/107after intracisternal infusion of MRI contrast agents and
found that two key components of the glymphatic system
(i.e. para-arterial CSF tracer influx and size-dependent
CSF-ISF exchange) could be visualized with dynamic
contrast-enhanced MRI. In order to permit comparison
with this prior study [20], in the present study intracisternal
and lumbar infusions in rats were conducted in the
same manner: an infusion rate of 1.6 μl/min for each
of the 30, 60, 120, and 180 min groups. Infusion was
stopped at a total volume of 70 μl. At t = 30, 60, or
120 min after the start of infusion, rats were transcardially
perfused with ice-cold heparinized PBS, followed by 4%
paraformaldehyde (PFA). Brains were removed, post-fixed
overnight in 4% PFA at 4°C, and 50 μm coronal slices
were cut on a vibratome (Leica) and mounted with
PROLONG Anti-Fade Gold with DAPI (Invitrogen). For
studies conducted in mice, TR-d3 was infused via the
cisterna magna at a rate of 1.6 μl/min for 6.25 min (total
volume = 10 μl). This infusion volume was the same
as was used previously to define perivascular CSF-ISF
exchange by in vivo 2-photon microscopy [16].
In a separate group of animals, we evaluated the effect of
tracer infusion upon intracranial pressure (ICP). A 22GA
ICP cannula was inserted stereotactically into the right
lateral ventrical and the animal allowed to equilibrate
for 30 min. In the first animals, we sequentially increased
intracisternal CSF tracer infusion rates from 1.6 to 3.2 to
6.4 μl/min to define the rate that would not evoke an
acute elevation of ICP. In 2 additional groups of animals
(n = 4 each), we measured ICP during 60 min infusions of
CSF tracer via the cisterna magna and the lumbar spine.Immunofluorescence
Free floating immunofluorescent labeling was conducted
on a separate set of 50 μm slices. For intracisternal infu-
sion, 8 slices from each animal (n = 3 to 4 rats per time
point) from the 60 min time point were used. For lum-
bar infusion, 8 slices from each animal from the 120 min
time point were used. These time points were chosen
based on pilot data, because they corresponded with
peak CSF tracer influx via the respective infusion routes.
Slices were blocked in 3% normal donkey serum (Jackson
Immunoresearch) for 1.5 hrs at room temperature, incu-
bated in mouse anti-glial fibrillary acidic protein (GFAP,
an astrocytic marker; 1:1000, Millipore) or Biotinylated
Griffonia (Brandeiraea) Simplicifolia Lectin I Isolectin
B4 (Ib4, a vascular endothelial marker; 1:100, Vector
Laboratories) overnight at 4°C. Secondary detection was
conducted for mouse-anti GFAP using Cy5-conjugated
donkey anti-mouse secondary antibody (1:500, Jackson
Immunoresearch) and for Ib4 using Cy5-conjugated strep-
tavidin (1:250, Jackson Immunoresearch). Slices were in-
cubated for 2 hrs at room temperature in the secondaryantibody solution. After washing, all slices were mounted
with PROLONG Antifade Gold with DAPI (Invitrogen).
Fluorescence imaging
Tracer movement into the brain was measured by con-
ventional fluorescence microscopy. Whole slice 3-channel
montages were generated at 4x magnification for 8
slices per animal using the Virtual Slice module of the
Microlucida software (Microbrighfield), on an upright
fluorescence microscope (Olympus) equipped with a
motorized stage. This included separate DAPI, green
(for FITC) and red (for Texas Red) emission channels.
The gain and exposure settings were determined based
on un-infused control slices and held constant through-
out all imaging sessions. Slice fluorescence (fluorescent
tracer accumulation) was quantified using ImageJ soft-
ware (NIH), as described previously [16]. Anatomical
brain regions of interest (ROIs) were generated based
upon the DAPI emission channel for the cortex, white
matter (including corpus callosum, internal and external
capsule), subcortical structures (striatum, thalamus, hypo-
thalamus) and hippocampus. The background fluores-
cence for each channel was uniformly subtracted and
the mean pixel intensity for each region was measured.
Distribution of large and small molecular weight CSF
tracers throughout the brain parenchyma was evaluated
under high power by laser scanning confocal micros-
copy (Olympus). Immunofluorescently-labeled slices were
imaged at 40X objective power.
Statistical analysis
All values are expressed as mean ± SEM. Intensities were
compared at each time point and across infusion routes
by 2-way analysis of variance (ANOVA) with Bonferroni’s
post-hoc test to evaluate differences at individual time
points (Graphpad Prism software). A ‘P’ value < 0.05 was
considered significant.
Results and discussion
In two recent studies, 2-photon in vivo imaging in mice
and dynamic contrast-enhanced MRI in rats were used
to demonstrate the existence of a brain-wide perivascu-
lar route, termed the ‘glymphatic pathway’, that permits
CSF to exchange with the brain ISF [16,20]. CSF-ISF ex-
change along these perivascular pathways was supported
by astroglial aquaporin-4 water channels and the move-
ment of fluid through this pathway facilitated the clear-
ance of interstitial solutes, including soluble Aβ, from
the brain. The purpose of the present study was to assess
whether a clinically relevant lumbar intrathecal route of
CSF tracer delivery could be used to visualize perivascular
CSF-ISF exchange in the brain. In contrast to our initial
study, which was performed on mice, the current study
characterized glymphatic flow in the adult Sprague Dawley
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tion into a new species, while also moving to a model sys-
tem that makes it easier to perform lumbar intrathecal
infusions. Intracisternal CSF tracer infusions were carried
out in a parallel group of animals to provide a direct com-
parison to the infusion route used previously [16,20].Effect of intrathecal lumbar and cisternal tracer infusion
upon intracranial pressure
Although a bolus injection would be the easiest to trans-
late to the clinical setting, we found in pilot studies that
the intracranial hypertension resulting from a bolus
injection of fluorescent tracer or contrast agent at the
cisterna magna was fatal. This limitation would likely
not be a factor in larger species, such as non-human
primates or humans. When ventricular ICP was measured
in rats during intracisternal TR-d3 infusion, we observed
that infusing at a rate of 1.6 μl/min did not appreciatively
alter ICP (Figure 1A). When infusion rate was increased
to 3.2 and 6.4 μl/min, a progressive elevation in ICP
was noted (Figure 1A). Based upon these findings, we
conducted lumbar and intracisternal tracer infusion at
1.6 μl/min for 60 min and measured the effect upon
ICP. We observed that in the rat under the present
anesthetic conditions, a tracer infusion rate of 1.6 ul/min
did not significantly alter ICP (Figure 1B).Figure 1 Defining the effect of intrathecal tracer infusion on
intracranial pressure (ICP). Ventricular ICP was monitored
continuously during infusion of CSF tracer Texas Red-conjugated
dextran (TR-d3, MW 3 kD) in rats. (A) Intracisternal TR-d3 infusion
at 1.6 ul/min did not appreciatively alter ICP, whereas increasing
the infusion rate to 3.2 and 6.4 ul/min significantly elevated ICP.
(B) Intracisternal and lumbar infusion of TR-d3 did at 1.6 μl/min for
60min did not significantly alter ICP (n = 4 per group).Imaging CSF-ISF exchange in mouse and rat by
intracisternal tracer infusion
We next characterized the movement of intrathecal CSF
fluorescent tracer (TR-d3) into the rat brain parenchyma
after infusion via the cisterna magna. Figure 2A-B, D-E
shows representative images from mouse and rat brain
slices taken 1.1 and 1.0 mm, respectively, anterior and
1.5 and 0.4 mm, respectively, posterior to Bregma, that
were fixed 30 min after the start of tracer infusion (the
time point of peak fluorescence intensity). Under the same
imaging conditions, un-infused brain tissue exhibited only
limited fluorescence (Figure 2C,F). Consistent with our prior
study in mice [16], we observed that intracisternally-infused
TR-d3 moved rapidly into the rat brain parenchyma, both
across the pial surface and along perivascular pathways
(Figure 2B,E) and exchanged broadly with the brain
interstitium. To quantify tracer movement into different
brain regions, we defined four anterior (Figure 2G-H)
and posterior (Figure 2I-J) regions of interest including
the cortex, white matter, subcortical structures, and
hippocampus (Figure 2G,I show the regions of interest).
Analysis of TR-d3 fluorescence either within the whole
ex vivo slice or within the individual regions revealed
that the influx of intracisternally-infused CSF tracer
peaked around 30 min post-infusion, then began to de-
cline at later time points as the tracer was cleared fromthe brain tissue (Figure 2H,J; n = 3–4 animals per time
point).
Analysis of tracer clearance between the four different
anatomical regions suggested that tracer clearance from
subcortical structures was faster than from the cortex
(Figure 2H,J; *P < 0.05 cortex vs. subcortical, 2-way
ANOVA). This is consistent with our prior observation
that subcortical regions enjoy the largest influxes of sub-
arachnoid CSF along large caliber penetrating arteries
from the ventral brain surface [16]. Furthermore, these
regions are most proximate to the para-venous clear-
ance pathways that drain medially along the internal
cerebral veins. When anterior versus posterior tracer
fluxes were compared, both peak values at 30 min and
the rate of clearance between 30–120 min post-infusion
were lower in the posterior brain compared to the an-
terior brain (compare Figure 2H,J). These observations
are consistent with MRI findings in the rat in which
Figure 2 Evaluating intracisternal CSF tracer influx and clearance in mouse and rat. Representative anterior (A-B) and posterior (D-E)
coronal slices from mouse (A, D) and rat (B, E) brains following intracisternal infusion of Texas Red-conjugated dextran (TR-d3, MW 3kD; t = 30min
post-infusion) show similar tracer distributions between species. (C, F) Un-infused rat brain slices exhibit little tissue autofluorescence. (G-J) Tissue
fluorescence was evaluated in different brain regions: cortex (blue), white matter (grey), hippocampus (magenta), and subcortical structures (red)
of the anterior (G-H) and posterior (I-J) brain. (H, J) Quantification of mean fluorescence intensity within each region (*P < 0.05 cortex vs.
subcortical structures; ##P < 0.01 cortex vs. white matter structures; 2-way ANOVA; n = 3–4 per time point). Dashed line indicates average gray
matter tissue autofluorescence level.
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both faster and greater in magnitude than those that
followed branches of mediolateral arteries such as the
middle cerebral artery [20]. In both the anterior and
posterior brain, TR-d3 fluorescence intensity in the white
matter was significantly lower than the cortex at all time
points (Figure 2H,J; ##P < 0.01 vs. cortex, 2-way ANOVA),
while the rate of tracer clearance from the white matter
did not appear to consistently differ from other brain re-
gions. The shift in white matter fluorescence intensity
likely stems from lower levels of tissue autofluorescenceof white matter compared to gray matter. Alternatively,
this may reflect the lower levels of CSF tracer penetra-
tion into the subcortical white matter observed in our
prior study [16].
Imaging rat CSF-ISF exchange following lumbar
intrathecal infusions
Compared to intracisternally-infused TR-d3 (Figure 2H,J),
the influx of CSF tracer delivered by the lumbar route was
significantly delayed, peaking in the posterior brain 60 min
after infusion, and in the anterior brain 120 min after
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delay in CSF tracer influx kinetics is likely attributable
to two factors. First, the distance from the site of lumbar
infusion to the cisterna magna is ~32 mm. Second, the
prevailing direction of CSF bulk flow within the spinal
subarachnoid is rostral-to-caudal [28], suggesting that
during infusion, CSF tracer must traverse the interven-
ing distance against the bulk CSF flow generated from
CSF secretion in the cerebral ventricles. In addition to
the delay in fluorescent CSF tracer influx, the overall
magnitude of tracer influx into the brain was markedly
reduced after lumbar infusion compared to intracisternal
infusion. The density of the infusate likely did not play a
significant role in directing tracer distribution or kinetics,
as the infusate consisting of either of the two tracers was
determined to be isobaric to the CSF. This difference isFigure 3 Effect of molecular weight on tracer influx into the brain aft
penetration of large molecular weight FITC-conjugated dextran (FITC-d500,
dextran (TR-d3, MW 3kD) 120 min after lumbar intrathecal co-infusion. FITC
moves readily though the brain parenchyma from perivascular spaces (A, a
fluorescent tracer influx into anterior (C-D) and posterior (E-F) brain after lu
matter, subcortical structures, and hippocampus.(*P < 0.05, *P < 0.01 cortex
††P < 0.01 cortex vs. hippocampus; 2-way ANOVA; n = 3-4 per time point).most likely the result of CSF reabsorption that occurs
along the spinal column via the peripheral nerve roots
[29], or perhaps subarachnoid CSF diversion along spinal
cord perivascular routes and into the central canal, as has
been reported following lumbar intrathecal infusion of
horseradish peroxidase [30]. As CSF tracer is infused into
the lumbar subarachnoid space and moves rostrally to-
wards the brain, a portion will be deposited along each
vertebral segment along the natural CSF clearance path-
way, resulting a reduced delivery of tracer to the distant
cisternal spaces surrounding the brain which form the
entrance to the brain-wide glymphatic system [16,20].
Despite these differences in influx magnitude and kinetics,
tracer distribution after lumbar and intracisternal infusion
followed a similar pattern and encompassed the entire
brain parenchyma (compare Figure 2B,E and Figure 3A).er lumbar intrathecal infusion. (A-B) Coronal brain slices show
MW 500kD) and small molecular weight Texas Red-conjugated
-d500 is largely confined to perivascular spaces (B, arrows), while TR-d3
rrows) or from the pial surface (arrowheads). (C-F) Quantification of
mbar intrathecal infusion, anatomically subdivided into cortex, white
vs. subcortical structures; ##P < 0.01 cortex vs. white matter; †P < 0.05,
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tracer influx into and through the brain parenchyma can
be readily visualized after infusion via a lumbar route.
Rat lumbar intrathecal tracer influx is independent of
molecular weight
CSF moves through the ventricular and subarachnoid
compartment through the process of bulk flow [13,31,32].
Because under bulk flow, the movement of the solvent
is typically more rapid than the movement of the solute
by passive diffusion, bulk flow-dependent movement is
largely independent of molecular weight [31]. To evalu-
ate whether the rate of intrathecal lumbar tracer influx
into the brain parenchyma was dependent upon mo-
lecular size, we co-infused large molecular weight fluor-
escent FITC-d500 (MW 500 kD) and small molecular
weight TR-d3 (MW 3 kD). Representative images from
this study are shown in Figure 3A-B. When FITC-d500
and TR-d3 movement into the brain parenchyma were
quantified within the anterior and posterior cortex, white
matter, subcortical structures and hippocampus, no sig-
nificant differences were observed between either the timeFigure 4 CSF tracer localization after intracisternal and lumbar intrathe
MW 500kD) and Texas Red-conjugated dextran (TR-d3, MW 3 kD) 30 min afte
restricted to perivascular spaces (arrows) surrounding penetrating arteries (A-B
Small molecular weight TR-d3 moved quickly into the brain interstitium and w
after lumbar intrathecal infusion of tracers, large molecular weight FITC-d500
observed after intracisternal infusion. Small molecular weight TR-d3 moved re
background green and red fluorescence in tissue from animals not injected w
isolectin B4 (vascular endothelial marker).course or the magnitude of influx of the small and large
molecular weight tracers (Figure 3C-F). This finding is
consistent with the movement of fluorescent tracer from
the lumbar site of infusion to the brain subarachnoid and
perivascular spaces via bulk flow rather than by simple
diffusion [31].
Perivascular pathway of intracthecal CSF tracer influx
In our prior study in mice [16], we noted that while CSF
tracers of all sizes moved rapidly into the brain along
perivascular spaces, large molecular weight tracers such
as FITC-d2000 (MW 2000 kD) became trapped in the
perivascular space and could not move freely into and
through the brain interstitium. According to one recent
study, astrocytic endfoot processes completely cover the
cerebral microcirculation; the only routes between the
perivascular spaces and the wider brain interstitium being
through ~20 nm clefts between overlapping astroglial
endfeet [33]. We surmised that the perivascular astro-
cytic endfeet acted as a sieve to restrict the movement
of large solutes from the perivascular spaces into the
brain interstitium [16]. This is consistent of with diameterscal infusion. (A-F) Localization of FITC-conjugated dextran (FITC-d500,
r intracisternal infusion. Large molecular weight FITC-d500 remained
) and extending to the level of the terminal capillary beds (C-F, arrows).
as taken up by subpopulations of neurons (arrowheads). (G-L) 120 min
accumulated in perivascular spaces (arrows), but not as uniformly as
adily throughout the brain parenchyma. Inset (L) depicts IB4 staining and
ith CSF tracer. GFAP: glial fibrillary acidic protein (astrocytic marker); IB4:
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and 500 kD dextrans (>20 nm) [34].
In the present study, we utilized confocal microscopy
to evaluate small (TR-d3) and large (FITC-d500) fluores-
cent CSF tracer exchange between the perivascular
influx pathway and the surrounding brain interstitium.
We fixed slices from intracisternally-infused animals and
lumbar-infused animals at 30 and 120 min after infusion,
respectively. These time points corresponded to the peak
influx values observed for each infusion route (Figures 2–3).
Following intracisternal infusion, FITC-d500 covered the
pial surface and distributed into deeper brain tissue along
perivascular pathways, extending to the level of the ter-
minal capillary beds (Figure 4A-F). It did not move appre-
ciably from the perivascular spaces into the surrounding
interstitium. When FITC-d500 distribution was evaluated
after lumbar infusion, the large molecular weight tracer
in a similar manner remained confined to perivascular
spaces (Figure 4G-L), however the overall fluorescence
intensity was reduced compared to intracisternal infusions.
After both intracisternal and lumbar infusion, small mo-
lecular weight tracer moved readily into the interstitium
surrounding perivascular spaces (Figure 4A-L). Import-
antly, when tissue was processed and imaged from animals
not undergoing CSF tracer injection, background green
and red fluorescence was negligible (Figure 4L, inset),
indicating that observed tissue fluorescence stemmed
from the influx of fluorescent CSF tracer. These data
demonstrate that after both intracisternal and lumbar
intrathecal infusion in the rat, large molecular weight
fluorescent tracers move into the brain along perivascu-
lar spaces, but remain confined to this space. Small mo-
lecular weight CSF tracers, in contrast, are able to move
into and through the brain interstitium.
Conclusion
In the present pre-clinical study, we report that perivas-
cular CSF-ISF exchange within the rat brain can be eval-
uated following infusion of CSF tracer via a lumbar, in
addition to an inctracisternal, route. In order to translate
the initial characterization of the glymphatic pathway
to a clinical setting, it is necessary to use a clinically
relevant methodology for CSF tracer and contrast in-
fusion as well as imaging modality for evaluation of
glymphatic pathway function. A recent analysis showed
that the glymphatic system can be evaluated in the rats
using contrast-enhanced MRI following intracisternal
gadolinium-based contrast infusion [20]. Intracisternal in-
fusions, however, are rarely used in a clinical setting due
to their high potential for iatrogenic complications, in-
cluding traumatic tissue injury [17]. In contrast, the lum-
bar intrathecal delivery route is routinely employed for
administration of contrast for CT-myelography [23,25],
spinal anesthetics and post-operative analgesics [35,36], aswell as chemotherapeutics [37]. By utilizing an intrathecal,
rather than a trans-blood brain barrier route for contrast
delivery, the difficulties associated with therapeutic agent
delivery into the CNS [38] can be circumvented.
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